Teladoc Health Q2 revenue $652M (+10% YoY); adj EBITDA $72.2M beats outlook

Teladoc Health, Inc.

2023-Q2 EPS reported -$0.82 revenue$1,281,650,000

Revenue $652.4M (+10% YoY); Integrated Care $360.1M (+5%), BetterHelp $292.4M (+18%).
Net loss $65.2M ($0.40/share) vs $3.1B loss in Q2 2022 which included $3.03B goodwill impairment.
Adjusted EBITDA $72.2M (+54% YoY), exceeding expectations; operating cash flow $101.2M.
Q3 2023 guidance: revenue $650-$675M, adj EBITDA $72-$82M; full-year adj EBITDA $300-$325M.
U.S. Integrated Care members guided at ~86 million for Q3 and full year 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Teladoc Health, Inc. reported Six Months Ended June 30, 2023 results: revenue $1,281.7 million, net income $134.4 million loss, EPS $0.82 loss per share.

Period: Six Months Ended June 30, 2023
Revenue: $1,281.7 million
Net income: $134.4 million loss
EPS: $0.82 loss per share
Result: reported results

Exact text from the filing

quarter 2022. Adjusted gross margin (1) was 70.8% for second quarter 2023, compared to 69.2% for second quarter 2022. Six Months Ended June 30, 2023 Revenue increased 11% to $1,281.7 million from $1,157.7 million in the first half of 2022. Access fees revenue grew 12% to $1,126.5 million, and other revenue grew 5% to $155.1 million. U.S. revenue grew 9% to $1,103.4

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Teladoc Health, Inc. reported Year ending December 31, 2023 results: revenue $2,600 - $2,675 million, EPS ($1.60) - ($1.25) loss per share. Guidance initiated.

Period: Year ending December 31, 2023
Revenue: $2,600 - $2,675 million
EPS: ($1.60) - ($1.25) loss per share
Guidance: initiated
Result: guidance update

Exact text from the filing

For the year ending December 31, 2023, we expect: Full Year 2023 Outlook Range Revenue $2,600 - $2,675 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Teladoc Health, Inc. reported Third quarter 2023 results: revenue $650 - $675 million, EPS ($0.50) - ($0.40) loss per share. Guidance initiated.

Period: Third quarter 2023
Revenue: $650 - $675 million
EPS: ($0.50) - ($0.40) loss per share
Guidance: initiated
Result: guidance update

Exact text from the filing

For third quarter 2023, we expect: 3Q 2023 Outlook Range Revenue $650 - $675 million

View on SEC.gov

Browse all earnings releases →

Teladoc Health, Inc. filing history →

Source: SEC EDGAR

accession 0001477449-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.